Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

45.5%

5 terminated/withdrawn out of 11 trials

Success Rate

37.5%

-49.0% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

N/A

5(45.5%)

Phase 2

3(27.3%)

Phase 3

2(18.2%)

Phase 1

1(9.1%)

11Total

N/A(5)

Phase 2(3)

Phase 3(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT03377517Not ApplicableTerminated

Radiosurgical Hypophysectomy for Bone Metasteses Pain

Role: collaborator

NCT02701088Phase 2Active Not Recruiting

Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life

Role: collaborator

NCT06360653Not ApplicableRecruiting

a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer

Role: collaborator

NCT00643617Not ApplicableCompleted

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

Role: lead

NCT00643994Not ApplicableCompleted

CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution

Role: lead

NCT02716948Phase 1Completed

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Role: collaborator

NCT00643318Phase 2Unknown

CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

Role: lead

NCT00840749Not ApplicableTerminated

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

Role: lead

NCT01318447Phase 2Terminated

CyberKnife® for Hepatic Metastases From Colorectal Cancer

Role: lead

NCT01327521Phase 3Withdrawn

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Role: collaborator

NCT01318200Phase 3Withdrawn

Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

Role: lead

All 11 trials loaded